Lary C. Walker

Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice.

Proteopathy: the next therapeutic frontier?

Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice.

Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.

Xanthomatosis.

Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta).

Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta).

Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.

Proteomic identification of the involvement of the mitochondrial rieske protein in epilepsy.

Emerging prospects for the disease-modifying treatment of Alzheimer's disease.

The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.

Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice.

Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease.

Alzheimer therapeutics-what after the cholinesterase inhibitors?

Inducible proteopathies.

Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.

MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.

The response of the aged brain to stroke: too much, too soon?

Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically.

Long-term hypothermia reduces infarct volume in aged rats after focal ischemia.

Tauopathy with paired helical filaments in an aged chimpanzee.

Molecular polymorphism of Abeta in Alzheimer's disease.

Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors.

PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.

Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?

Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation.

Ovarian aging in squirrel monkeys (Saimiri sciureus).

Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

The grandmother effect and the uniqueness of the human aging phenotype.

Mosaic aging.

Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.

Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.

Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI.

Amyloid by default.

The role of the ATP-binding cassette transporter P-glycoprotein in the transport of β-amyloid across the blood-brain barrier.

Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice.

Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition.

Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.

Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.

The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain.

Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy.